ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 13

Visfatin/Nampt in Osteoarthritis: Sites of Production in Human Joints and Role of Its Enzymatic Activity

Marie-Charlotte Laiguillon1, Carole Bougault1, Xavier Houard2, Marjolaine Gosset3, Geoffroy Nourissat4, Sabrina Priam1, Zvezdana Mladenovic1, Claire Jacques1, Francis Berenbaum5 and Jeremie Sellam6, 1Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, 2Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, 3EA 2496, Paris Descartes University, Montrouge, France, 4Orthopaedic Surgery and Traumatology, Pierre et Marie Curie University Paris VI, Paris, France, 5Rheumatology, AP-HP, St Antoine Hospital, Paris, France, 6Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Adipocytokines, chondrocytes, osteoarthritis and osteoblasts

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: The role of cytokines produced by obese-derived adipose tissue, namely adipokines, in the pathophysiology of osteoarthritis (OA) is now well established. We recently suggested that one of them, visfatin, may play a role in OA by activating chondrocytes (1,2). Along with its cytokine effect, visfatin has an enzymatic activity called nicotinamide phosphoribosyltransferase (Nampt), which is the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide (NAD) biosynthesis from nicotinamide, an intracellular pathway involved in many biological processes including TNFα and IL-6 synthesis. Thus, we aimed to i) characterize the local site(s) of production of visfatin/Nampt by the human OA joint tissues ii) further investigate the role of its enzymatic activity in the expression of pro-inflammatory cytokines by chondrocytes and iii) determine whether visfatin/Nampt may also play a role in subchondral bone.

Methods: Human OA joint tissues (synovial membrane, cartilage, subchondral bone) from patients undergoing surgical knee replacement were incubated for 24h in serum-free media. Visfatin/Nampt release in media by the different tissues was evaluated using Western Blot and ELISA. Primary cultures of mouse chondrocytes and osteoblasts were stimulated with recombinant visfatin/Nampt (5µg/mL) for 24h. To determine the role of the enzyme activity, cells were pretreated or not 4h before visfatin/Nampt stimulation with APO866 (10nM), a pharmacologic inhibitor of Nampt activity (3). Effects of stimulation on IL-6, IL-8/Kc, IL-1β, MCP-1, VEGF and TGFβ expression, and on IL-6 and IL-8/Kc release were examined by quantitative RT-PCR and ELISA, respectively.

Results: All human OA joint tissues released visfatin/Nampt (synovium: 529 ± 356, cartilage: 237 ± 380, subchondral bone: 200 ± 104 ng/g tissue) with higher level for the synovium compared to cartilage (p<0.01). Visfatin/Nampt significantly induced IL-6, IL-8/Kc, IL-1β and MCP-1 expression by chondrocytes (n=6) and osteoblasts (n=5) (Table). Visfatin/Nampt increased the production of IL-6 and IL-8/Kc proteins by both cell types. Nampt activity inhibition by APO866 decreased pro-inflammatory cytokines expression at mRNA level (up to 97 % of inhibition) as well as at protein level (up to 63 % of inhibition) and was especially efficient in chondrocytes (Table). Effect of visfatin/Nampt was selective since VEGF and TGFβ were not modulated upon stimulation.

 

Gene expression

Protein production

IL-6

Kc/IL-8

IL-1β

MCP-1

IL-6

Kc/IL-8

Chondrocytes (n=6)

Fold induction after visfatin/Nampt stimulation (Mean ± SEM), p-value

10.6 ± 3 (p=0.015)

4.9 ± 1.3 (p=0.015)

878 ± 320 (p=0.015)

2.5 ± 0.4 (p=0.03)

5.8 ± 5 (p=0.016)

29.7 ± 33 (p=0.015)

Mean % of inhibition by APO866

94 %

83 %

97 %

62 %

63 %

57%

Osteoblasts (n=5)

Fold induction after visfatin/Nampt stimulation (Mean ± SEM), p-value

296 ± 59 (p=0.03)

142 ± 64 (p=0.03)

396 ± 112 (p=0.03)

133 ± 83 (p=0.03)

51 ± 19 (p=0.05)

54 ± 23 (p=0.05)

Mean % of inhibition by APO866

63 %

79 %

73 %

84 %

39 %

49%

Conclusion: Visfatin/Nampt is produced by the cartilage, the subchondral bone and mostly by the synovial membrane. We demonstrate that Nampt activity of visfatin plays a major role in chondrocytes and osteoblasts activation, suggesting that targeting the Nampt enzymatic activity with a compound like APO866 (being tested in hematological malignancies) may be a new therapeutic approach of OA.

References: (1)Gosset M. Arthritis Rheum 2008 (2) Jacques C. J Biol Chem 2012 (3) Busso N. PLoS One 2008


Disclosure:

M. C. Laiguillon,
None;

C. Bougault,
None;

X. Houard,
None;

M. Gosset,
None;

G. Nourissat,
None;

S. Priam,
None;

Z. Mladenovic,
None;

C. Jacques,
None;

F. Berenbaum,
None;

J. Sellam,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2012

ACR Meeting Abstracts - https://acrabstracts.org/abstract/visfatinnampt-in-osteoarthritis-sites-of-production-in-human-joints-and-role-of-its-enzymatic-activity/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology